Effect of Herbal Echinacea on Recurrent Minor Oral Aphthous Ulcer
Faezeh Khozeimeh1, Zahra Saberi1, *, Atefeh Tavangar2, Fahime Fakhari Badi3
Identifiers and Pagination:Year: 2018
First Page: 567
Last Page: 571
Publisher ID: TODENTJ-12-567
Article History:Received Date: 31/3/2018
Revision Received Date: 28/6/2018
Acceptance Date: 16/7/2018
Electronic publication date: 31/08/2018
Collection year: 2018
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: (https://creativecommons.org/licenses/by/4.0/legalcode). This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The oral aphthous is a common oral ulcer with intense pain and there is no treatment for it, yet. Echinacea is an herbal medicine that moderated the immune system.
The aim of this study was to investigate the effects of Echinacea on the treatment of aphthous ulcer.
50 patients with minor aphthous participated in our study. 25 patients take 3 tablets in a day for five weeks (case group) and 25 patients didn’t take any tablets (control group). The patients were monitored for one month before taking the tablets for six months. During this period, the number of lesions, complete improvement of ulcers, recurrence rate and intensity of pain were considered in each month. Finally, the Friedman and ANOVA tests used to analyze the obtained data.
Our study showed a significant difference between a number of lesions during six-month in case and control groups (p>0.001). In this way, we observed that the number of lesions was decreased significantly after six months in the case group. Hence, ANOVA analysis showed a significant decrease between each month for the intensity of pain (p=0.025), complete improvement (p<0.001) and recurrence rate (p=0.026).
In conclusion, we showed that Echinacea tablets as an herbal medicine have positive effects on a number of lesions, intensity of pain, complete improvement and recurrence rate in patients with recurrent minor aphthous ulcers.
An aphthous ulcer is a common oral mucosa problem, which is a solitary lesion, circular, symmetric and shallow . The clinical symptoms of aphthous have three categories: minor aphthous ulcers, major aphthous ulcers and herpetiformis ulcers. Etiology of aphthous is unclear and treatment methods are non-specific and based on experimental studies . Aphthous treatments should be proportionate to its intensity and symptoms. Nowadays, many medicinal plants are used for the treatment of aphthous, such as mouthwash of Salvia (Salivia oficinalis), chamomile, Carrot, pomegranate (Punica granatum), Water Melon (Cantaloupe), wild geranium, Aloe vera and liquorice . Some plant compounds have been proposed as reinforcing the immune system in the treatment of diseases involving the immune system, which can be noted to the Echinacea purpurea plant . From the early 17th century, the natives of America used Echinacea to treat snake bites, gums and mouth diseases, colds, cough, sore throat and blood poisoning. Moreover, this plant used to treat scarlet fever, syphilis, malaria and diphtheria, traditionally. The Echinacea effects in improvement of ulcer and disinfection were discussed and approved in 1920 . The chemical components of Echinacea plant species include lipophilic, water-soluble polysaccharides, caffeic acid derivatives and chicoric acid . The alkaloids, polysaccharides and chicoric acid in this plant were stimulating the immune system . The polysaccharides in this plant have anti-inflammatory properties and stimulate the fibroblasts to repair damaged connective tissue . The polysaccharide in this plant stimulates the immune system by increasing the production of T cells and other white blood cells, activation of macrophages and monocytes, and increase production of polymorphonuclear (PMN) [8, 9]. Each Echinacea tablet contains 114 mg dried leachate of Echinacea purpurea plant, which does not recommend its oral administration for more than eight weeks and non-food consumption more than three weeks [5, 8].
Since recurrent aphthous is one of the most common oral diseases, a large percentage of people suffer from this disease. A significant cause of aphthous was impaired immune system, therefore the aim of this study was to investigate the efficacy of Echinacea tablets on the complications of recurrent minor oral aphthous ulcer disease.
2. MATERIALS AND METHODS
This study is a clinical trial. 50 patients were selected among those referred persons to the centers and dental clinics in Isfahan-Iran with minor aphthous ulcers. The subjects were diagnosed with minor aphthous over the past year, which occurs at least once in two months. The pregnant and lactating patients, consumers of systemic steroids, immune system modulators and non-steroidal anti-inflammatory drugs, as well as patients with a history of ulcerative colitis, Crohn disease, Behcet's disease, and severe anemia, life-threatening diseases such as severe heart, kidney and liver disease were excluded from this study.
After completing the form of informed consent, 25 patients received 105 Echinacea tablet as case group (Immustim Tablet, Flower medicine pharmacy, Iran). The oral administration of the drug program was started from first day of the next recurrent aphthous for five weeks, and 3 tablets daily. Thus, patients from a recurrent before drug use to recurrences occurred after taking the drug were monitored monthly, in six months. The number of lesions, duration of complete improvement (according to day), recurrent intervals and pain intensity (according to VAS) were recorded at each recurrence. Also, the other 25 patients don’t use any tablet within six months (control group).
Finally, obtained results within 6 months were analyzed using the SPSS software (version 22). The Friedman test and analysis of variance were used for repeated data analysis (α=0.05). This clinical trials code is (IRCT) IRCT2016012626209N1.
All subjects were monitored from a recurrent before taking the drug to recurrent after taking the first drug monthly, for six months. Each month, the average number of lesions, pain intensity, duration of complete improvement and recurrent intervals were calculated and finally, the periods in case and control groups were compared.
|Ave/SD||First Month||Second Month||Third Month||Fourth Month||Fifth Month||Sixth Month|
|Number of Lesions||(0±0.97) 1.88||(0±0.54) 1.48||(0±0.38) 1.21||(0±0.4) 1.22||(0±0.28) 1.10||(0±0.033) 1.12|
|Pain Intensity||(0±1.44) 8.17||(1±0.77) 6.63||(2±0.17) 6.71||(2±0.1) 6.59||(2±0.9) 6.42||(0±2.19) 6.24|
|Remission Duration||(3±0.33) 9.57||(3±0.33) 6.88||(3±0.47) 7.91||(3±0.26) 7.65||(3±7.35) 7.12||(0±6.60) 6.60|
|Recurrent Intervals||(14±0.35) 18.39||(12±0.23) 22.4||(17±0.56) 26.3||(15±0.6) 23.81||(19±0.55) 28.0||(19±0.01) 30.06|
The obtained results from the Friedman test showed significant differences between numbers of lesions in one-month intervals and between case and control groups. Also, variance analysis (ANOVA) for frequent data showed significant differences between the average of pain intensity, duration of complete remission and recurrent intervals in a period of six months, and between case and control groups (Table 1 and Fig. 1). Finally, paired sample t-test and Wilcoxon tests have been shown a significant difference between the studied variables (Table 2).
|Recurrent Intervals||Remission Duration||Pain Intensity||Number of Lesions||Month|
|0.000||0.003||0.000||0.012||1 and 2|
|0.002||0.033||0.001||0.003||1 and 3|
|0.004||0.004||0.004||0.002||1 and 4|
|0.001||0.001||0.000||0.000||1 and 5|
|0.000||0.000||0.000||0.000||1 and 6|
|0.263||0.553||0.927||0.034||2 and 3|
|0.168||0.160||0.957||0.033||2 and 4|
|0.227||0.964||0.429||0.002||2 and 5|
|0.018||0.211||0.254||0.010||2 and 6|
|0.972||0.933||0.742||0.465||3 and 4|
|0.931||0.082||0.4.6||0.201||3 and 5|
|0.011||0.003||0.279||0.223||3 and 6|
|0.613||0.006||0.023||0.129||4 and 5|
|0.008||0.000||0.010||0.102||4 and 6|
|0.115||0.003||0.391||0.656||5 and 6|
|ANOVA: PV=0.026||ANOVA: PV<0.001||ANOVA: PV=0.025||Friedman: PV<0.001||General Test|
In this study, the effect of Echinacea tablets was studied on aphthous ulcers. Based on obtained results in this study, this drug has a positive effect on the number of lesions, intensity of pain, duration of complete improvement and recurrent intervals in patients. These effects may be due to the presence of polysaccharides in the Echinacea plant and stimulate the immune system. Thus, this plant is used for the treatment of common cold, respiratory tract infection, and also viruses ulcers such as syphilis, abscesses ulcers and swelling of the tonsils [4, 8, 9].
Echinacea is most widely used to strengthen the immune system against viral diseases that weaken the immune system. Therefore, topical administration of Echinacea preparations has positive effects in accelerating the improvement of ulcers and tissue repair. It is believed that this effect is related to inhibiting the activity of tissue hyaluronidase enzyme by substances contained in this plant .
In a study by Pascal P and Viguier S (2000), the efficacy of a daily dose of prednisolone (1mg/kg) and colchicine (2 mg/d) in 5 patients with aphthous was investigated. They demonstrated that prednisolone leads to the improvement of ulcers quickly and colchicine decreased the pain . In the present study, we showed that the Echinacea has similar effects with prednisolone (accelerate to improvement) and colchicine (reduction of pain) on patients with aphthous. Echinacea tablet is an herbal medicine and has fewer side effects than prednisone and colchicine, use of the Echinacea seems more appropriate in treating aphthous.
A study by Ilia Volkou et al., (2009) showed that the use of vitamin B12 by patients with aphthous leads to reduce pain, number of lesions and duration of improvement . In this regard, Matlabnejad et al., (2008) investigated the effect of tea plant extraction (Hypericum perforatum) on 30 patients with recurrent oral aphthous ulcers. They observed that 5.0% of Hypericum perforatum in mouthwashes has a positive impact on pain and improvement of minor aphthous ulcers . In the present study, in addition to reducing of pain and accelerating the improvement of recurrent aphthous, the Echinacea plant leads to decrease the number of aphthous ulcers and increase the recurrent intervals, which indicates the significant influence of this drug on the aphthous disease.
A study by Jahanshahi and Saniei (2012) examined the effect of triamcinolone drug on patients with aphthous disease. They showed that this drug in the second session decreases the size of the lesions (P = 0.026) and pain intensity (P=0.043) . In the present study, in addition to reduce pain, reduce the number of lesions and recurrent, and accelerate improvement. This study showed that Echinacea reduces the size of lesions in some patients. Of course, the aim of this study was not to investigate the size of lesions and recommend it to be considered in future research. Generally, according to this study, we can introduce the Echinacea as a first systemic drug for the treatment of aphthous ulcers.
The limitations of this study can refer to patient cooperation; because systemic drug consumption and lack of other drugs consumption in six months are difficult for patients. In this study, the effects of Echinacea drug were not compared with other drugs. Therefore, it is recommended that comparison must be done between this drug and other effective drugs on aphthous, in future studies.
The Echinacea tablet as a herbal medicine provides beneficial effects on the number of aphthous ulcers, intensity of pain, duration of complete improvement and recurrence intervals in patients with recurrent minor oral aphthous ulcer; and can be considered as an effective and affordable treatment method.
ETHICS APPROVAL AND CONSENT TO PARTICIPATE
The study protocol was approved by the Ethical Committees of Isfahan, University of Medical Science. This clinical trials code is (IRCT) IRCT2016012626209N1.
HUMAN AND ANIMAL RIGHTS
No animals were used in this research. All research procedures followed were in accordance with the ethical standards of the committee responsible for human experimentation (institutional and national), and with the Helsinki Declaration of 1975, as revised in 2008 (http://www.wma.net/en/20activities/10ethics/10helsinki/).
CONSENT FOR PUBLICATION
Written informed consent was obtained from the patient for publication of this study.
CONFLICTS OF INTEREST
The authors declare no conflict of interest, financial or otherwise.
The authors thank the participants for taking part in this study.